Inhibitions of complement C3 in patients with autoimmune haemolytic anemia controls haemolysis and increases haemoglobine levels
BestPractice | Jun 2019 | | EHA 2019
Autoimmune haemolytic anaemia is characterized by haemolysis mediated by autoantibodies directed against red blood cells. Complement C3b deposition on red blood cells plays a central role in autoimmune haemolytic anaemia. In this MEDtalk Bruno Fattizzo present new data that shows APL-2, a cyclic peptide, has potential as a novel therapeutic for autoimmune haemolytic anaemia.